A Study of IBI3032 in Chinese Healthy Participants and Participants With Overweight or Obesity

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 27, 2025

Primary Completion Date

November 3, 2025

Study Completion Date

March 31, 2026

Conditions

Part A: Healthy Part B: Overweight or Obesity

Interventions

DRUG

Placebo

Single dose placebo IBI3032 administered orally

DRUG

IBI3032 tablets

Single dose of IBI3032 administered orally

Trial Locations (1)

RECRUITING

Zhongshan Hospital affiliated to Fudan University, Shanghai

All Listed Sponsors

lead

Innovent Biologics Technology Limited (Shanghai R&D Center)

INDUSTRY